We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow
12 Mar 2024 - Baar, 12 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]
Read moreTransformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
15 Aug 2023 - Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO: Reported results […]
Read morePolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
13 Jul 2023 - Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide […]
Read morePolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
3 Apr 2023 - Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of […]
Read morePolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
14 Mar 2023 - Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]
Read moreCEO of PolyPeptide resigns
30 Jan 2023 - Baar, 30 January 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the resignation by […]
Read morePolyPeptide signs significant commercial agreement
19 Dec 2022 - Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a […]
Read morePolyPeptide provides market update
2 Dec 2022 - Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update. […]
Read morePolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
19 Aug 2022 - PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligo-nucleotide-based active pharmaceutical ingredients, today announced its detailed results for the first half of […]
Read more